Home » » Bharat Biotech’s 'Covaxin' gets SEC nod for phase 2-3 clinical trials on 2 to 18 year-olds

Bharat Biotech’s 'Covaxin' gets SEC nod for phase 2-3 clinical trials on 2 to 18 year-olds

No comments


from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3fcY3wP
via IFTTT
Share:  Facebook Twitter Google+

0 comments:

Post a Comment